Latest Clinical Trials News

Entropy Neurodynamics reported that all six patients in Cohort 1 of its Phase 2 BED trial maintained clinically meaningful improvement 12 weeks after two TRP-8803 infusions. Three patients experienced no binge-eating episodes during the 84-day follow-up, although the results come from a small, open-label study without a control group.

Dimerix has secured Mexican composition of matter protection for its Phase 2-ready kidney drug DMX-652 until June 2041. The grant expands the asset’s patent estate ahead of planned clinical testing in acute kidney injury, although it brings no new clinical data or regulatory approval.

Paradigm Biopharmaceuticals has drawn the remaining US$2 million available in Tranche 4 of its convertible note facility, adding approximately A$2.8 million to working capital. The funding comes as its fully enrolled Phase 3 knee osteoarthritis trial advances towards interim analysis and top-line results.

Immutep has narrowed eftilagimod alfa’s potential registration pathway to PD-L1-negative head and neck cancer and neoadjuvant soft tissue sarcoma after identifying product differences between manufacturing scales used in earlier studies and TACTI-004. A new 200 L manufacturing run is planned, but replacement trials are not targeted to start until the second half of 2027 and remain subject to regulatory, funding and partnering decisions.

Neurizon will redeem 1 million convertible notes held by Obsidian for US$1.15 million, while securing a two-month standstill on share sales. The biotechnology company says the transaction leaves it funded through the HEALEY ALS trial readout and completion.

Cleo Diagnostics has appointed Bio-Techne’s CLIA-certified U.S. laboratory Asuragen to run pivotal clinical validation for its pre-surgical ovarian cancer test. The approximately 1,470-sample program is intended to generate the evidence supporting a planned FDA 510(k) submission in the first half of calendar 2027.

A multimillion-dollar, multiyear NIH grant will fund an expanded access program for Neurizon’s investigational NUZ-001, potentially giving up to 200 US patients access to the therapy for as long as 96 weeks. The program is designed to add long-term safety, survival and biomarker data alongside the pivotal HEALEY ALS trial.

Prescient Therapeutics has given shareholders another week to participate in its A$7 million share purchase plan, citing delayed documentation and requests for more time. The capital raising is intended to fund PTX-100 through a planned December 2026 Dose Optimisation Committee meeting.

Neurizon has appointed Dr Chris Bremer as chief executive as its NUZ-001 ALS program moves towards topline Phase 2/3 results expected in late Q2 2027. The incoming CEO brings more than 20 years of pharmaceutical and biotechnology experience, including over US$1 billion in licensing transactions.

Arovella Therapeutics has released the first clinical batch of its off-the-shelf cell therapy ALA-101 and activated its inaugural trial site at The Alfred, setting the stage for patient dosing later this month.

Actinogen Medical (ASX:ACW) has clarified that no undisclosed information explains recent unusual trading in its shares, pointing instead to recent underwriting of options and published updates. The biotech also reaffirmed compliance with ASX rules and provided a detailed update on its lead Alzheimer’s drug Xanamem and ongoing clinical trials.

Cleo Diagnostics has received its first commercial batch of ovarian cancer test kits from Bio-Techne, marking the start of analytical validation critical for its FDA submission planned in early 2027.